ASXC Stock Overview
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Asensus Surgical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$0.77 |
| 52 Week Low | US$0.20 |
| Beta | 1.48 |
| 1 Month Change | -9.75% |
| 3 Month Change | -13.96% |
| 1 Year Change | -66.31% |
| 3 Year Change | -86.41% |
| 5 Year Change | -99.01% |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASXC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.1% | -4.4% | -3.7% |
| 1Y | -66.3% | -2.8% | 20.2% |
Return vs Industry: ASXC underperformed the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: ASXC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ASXC volatility | |
|---|---|
| ASXC Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ASXC's share price has been volatile over the past 3 months.
Volatility Over Time: ASXC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 208 | Anthony Fernando | www.asensus.com |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company’s products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue.
Asensus Surgical, Inc. Fundamentals Summary
| ASXC fundamental statistics | |
|---|---|
| Market cap | US$68.73m |
| Earnings (TTM) | -US$78.43m |
| Revenue (TTM) | US$8.58m |
8.0x
P/S Ratio-0.9x
P/E RatioIs ASXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASXC income statement (TTM) | |
|---|---|
| Revenue | US$8.58m |
| Cost of Revenue | US$13.16m |
| Gross Profit | -US$4.58m |
| Other Expenses | US$73.86m |
| Earnings | -US$78.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | -53.38% |
| Net Profit Margin | -914.46% |
| Debt/Equity Ratio | 0% |
How did ASXC perform over the long term?
See historical performance and comparison